Enoxaparin Ledraxen

What Is Enoxaparin Ledraxen and What Is It Used For?

Quick Answer: Enoxaparin Ledraxen is a low molecular weight heparin (LMWH) anticoagulant used to prevent and treat blood clots. It is most commonly prescribed for prophylaxis against deep vein thrombosis (DVT) after surgery, treatment of existing venous thromboembolism, prevention of clotting during haemodialysis, and management of acute coronary syndromes including unstable angina and NSTEMI.

Enoxaparin sodium, the active substance in Enoxaparin Ledraxen, belongs to a class of medicines known as low molecular weight heparins (LMWHs). These medicines are derived from standard (unfractionated) heparin through a process of chemical or enzymatic depolymerisation, resulting in shorter polysaccharide chains with a mean molecular weight of approximately 4,500 daltons. This gives enoxaparin distinct pharmacological advantages over unfractionated heparin, including more predictable anticoagulant activity, better bioavailability after subcutaneous injection, and a longer half-life that allows for once- or twice-daily dosing.

The primary mechanism of action involves binding to antithrombin III (AT III), a natural anticoagulant protein in the blood. This binding dramatically accelerates the ability of antithrombin III to inhibit coagulation Factor Xa – the pivotal enzyme in the coagulation cascade that converts prothrombin to thrombin. Unlike unfractionated heparin, which inhibits both Factor Xa and Factor IIa (thrombin) equally, enoxaparin has a significantly higher ratio of anti-Factor Xa to anti-Factor IIa activity (approximately 3.8:1), which contributes to its more targeted anticoagulant effect and potentially lower risk of bleeding complications.

Enoxaparin is listed on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its importance as a fundamental anticoagulant in global healthcare. It has been used clinically for over three decades and remains one of the most widely prescribed anticoagulants worldwide. The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have both approved enoxaparin for multiple clinical indications.

Approved Clinical Indications

Enoxaparin Ledraxen is approved for several important clinical uses. These indications are supported by robust clinical trial evidence and are endorsed by major international guidelines from organisations including the European Society of Cardiology (ESC), the American College of Chest Physicians (ACCP), and the National Institute for Health and Care Excellence (NICE).

• Prophylaxis of venous thromboembolism (VTE) in surgical patients: Prevention of DVT and PE in patients undergoing major orthopaedic surgery (hip or knee replacement), abdominal surgery, or other surgical procedures that carry a moderate to high risk of venous thromboembolism.
• Prophylaxis of VTE in acutely ill medical patients: Prevention of blood clots in hospitalised medical patients with restricted mobility who are at risk for VTE due to conditions such as heart failure, severe respiratory disease, or acute infections.
• Treatment of deep vein thrombosis (DVT): Treatment of established DVT, with or without associated pulmonary embolism, usually in conjunction with a transition to oral anticoagulant therapy.
• Prevention of clot formation during haemodialysis: Used in the extracorporeal circuit during haemodialysis sessions to prevent clotting in the dialysis tubing and filter.
• Acute coronary syndromes: Treatment of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI), in combination with aspirin, to reduce the risk of ischaemic events. Also used in ST-segment elevation myocardial infarction (STEMI) managed with thrombolytic therapy or percutaneous coronary intervention (PCI).

What Should You Know Before Taking Enoxaparin Ledraxen?

Quick Answer: Enoxaparin Ledraxen must not be used if you have active major bleeding, a history of heparin-induced thrombocytopenia (HIT), or severe uncontrolled hypertension. Special caution is needed in patients with renal impairment, low body weight, or those receiving neuraxial (spinal/epidural) anaesthesia due to the risk of spinal haematoma.

Before starting treatment with Enoxaparin Ledraxen, your healthcare provider will carefully assess whether this medicine is appropriate for you. Several important medical conditions and factors can affect the safety and dosing of enoxaparin. It is essential to inform your doctor about your complete medical history, all other medicines you are taking (including over-the-counter medicines and herbal supplements), and any allergies you may have.

Contraindications

Enoxaparin Ledraxen must not be used in the following situations:

• Hypersensitivity to enoxaparin sodium, heparin, or any other low molecular weight heparin, including any excipients in the formulation.
• Active clinically significant bleeding and conditions with a high risk of uncontrolled haemorrhage, including recent haemorrhagic stroke.
• History of heparin-induced thrombocytopenia (HIT) – a serious immune-mediated reaction to heparin that paradoxically causes blood clots. If you have previously developed HIT with any heparin product, enoxaparin must not be used.
• Active gastric or duodenal ulcer with a high risk of bleeding.
• Recent brain, spinal, or ophthalmic surgery where the risk of bleeding at the operative site could have devastating consequences.

Warnings and Precautions

Several clinical scenarios require particular caution when using enoxaparin. Your doctor will weigh the benefits of anticoagulation against the potential risks in these situations:

• Renal impairment: Enoxaparin is partly cleared by the kidneys. Patients with severe renal impairment (creatinine clearance below 30 mL/min) require dose reduction and careful monitoring of anti-Factor Xa levels, as drug accumulation increases bleeding risk.
• Low body weight: Women weighing less than 45 kg and men weighing less than 57 kg may have increased exposure to prophylactic doses and should be closely monitored.
• Elderly patients: Patients over 75 years, particularly those with reduced renal function, may be at increased risk of bleeding and require dose adjustments.
• Thrombocytopenia: Platelet counts should be measured before starting treatment and monitored regularly throughout therapy. If the platelet count falls significantly (below 100,000/mm³ or a decrease of 30–50% from baseline), treatment may need to be discontinued and alternative anticoagulation considered.
• Prosthetic heart valves: The use of enoxaparin in patients with mechanical prosthetic heart valves has not been adequately studied, and thrombotic events (including valve thrombosis) have been reported. Enoxaparin is generally not recommended as the sole anticoagulant in these patients.
• Bleeding risk: Use with caution in any condition associated with increased risk of haemorrhage, including recent ischaemic stroke, uncontrolled arterial hypertension, history of peptic ulcer disease, diabetic retinopathy, concurrent use of antiplatelet agents, and recent major surgery.

Pregnancy and Breastfeeding

Enoxaparin does not cross the placenta in significant amounts, making it one of the preferred anticoagulants when anticoagulation is required during pregnancy. Animal reproduction studies have not demonstrated direct foetal toxicity, though there is limited data from controlled clinical trials in pregnant women. The European Society of Cardiology (ESC) and the American College of Chest Physicians (ACCP) recommend LMWH as the anticoagulant of choice during pregnancy for most indications requiring anticoagulation.

However, pregnant women receiving enoxaparin require careful planning regarding delivery. The risk of spinal haematoma with epidural anaesthesia must be considered, and timing of the last dose before delivery needs careful coordination with the obstetric and anaesthesia teams. Enoxaparin should generally be withheld for at least 12 hours (prophylactic dose) or 24 hours (therapeutic dose) before planned neuraxial anaesthesia.

There is limited information on the excretion of enoxaparin in breast milk. The oral bioavailability of enoxaparin is negligible, meaning that even if small amounts are present in breast milk, it would not be expected to have any clinically significant effect on the nursing infant. Most guidelines consider enoxaparin to be compatible with breastfeeding, though you should discuss this with your healthcare provider.

How Does Enoxaparin Ledraxen Interact with Other Drugs?

Quick Answer: Enoxaparin Ledraxen can interact with many medicines that affect blood clotting. The most clinically significant interactions are with other anticoagulants (warfarin, DOACs), antiplatelet agents (aspirin, clopidogrel), and NSAIDs (ibuprofen, naproxen), all of which increase the risk of bleeding when used together.

Drug interactions with enoxaparin primarily involve medicines that also affect haemostasis (the blood clotting process). When enoxaparin is combined with other agents that impair clotting or platelet function, the risk of bleeding can be significantly increased. It is critical to inform your healthcare provider about all medicines you are taking, including prescription medicines, over-the-counter products, vitamins, and herbal supplements.

Major Interactions

The following combinations require particular caution and may necessitate dose adjustments, additional monitoring, or avoidance of the combination altogether:

Minor Interactions

The following interactions are generally less clinically significant but should still be considered:

• Systemic corticosteroids: High-dose or long-term corticosteroid use may increase the risk of gastrointestinal bleeding when combined with enoxaparin.
• Selective serotonin reuptake inhibitors (SSRIs): Antidepressants such as fluoxetine, sertraline, and citalopram can impair platelet function and may slightly increase bleeding risk.
• Herbal supplements: Garlic, ginkgo biloba, ginger, and fish oil supplements may have mild antiplatelet properties and could theoretically increase the risk of bleeding.
• Potassium-sparing diuretics and ACE inhibitors: Enoxaparin (like all heparins) may suppress aldosterone production, potentially leading to hyperkalaemia (elevated potassium levels), particularly in patients with diabetes or pre-existing renal impairment.

What Is the Correct Dosage of Enoxaparin Ledraxen?

Quick Answer: The dosage of Enoxaparin Ledraxen varies depending on the clinical indication. For DVT prophylaxis, the typical adult dose is 20–40 mg (2,000–4,000 IU) once daily by subcutaneous injection. For treatment of DVT/PE, the dose is weight-based at 1 mg/kg (100 IU/kg) twice daily or 1.5 mg/kg (150 IU/kg) once daily. Always follow your prescriber's instructions exactly.

Enoxaparin Ledraxen is available as a solution for injection in pre-filled syringes. The dosage is determined by your healthcare provider based on the clinical indication, your body weight, and your kidney function. It is critically important to use the exact dose prescribed – enoxaparin is a high-alert medication where dosing errors can lead to serious bleeding or inadequate anticoagulation.

Adults

For most adult indications, the dosing is standardised as outlined in the table above. The pre-filled syringe formulation of Enoxaparin Ledraxen (2,000 IU / 20 mg per 0.2 mL) is primarily designed for prophylactic dosing. For higher therapeutic doses, larger syringe sizes may be needed (available as other enoxaparin products in 40 mg, 60 mg, 80 mg, and 100 mg strengths). Your healthcare provider will prescribe the appropriate strength based on your individual needs.

The injection should be administered by subcutaneous injection into the abdominal wall. The patient should be lying down during the injection. The injection site should be alternated between the left and right anterolateral and posterolateral abdominal wall. The needle should be introduced its entire length vertically into a skin fold held between the thumb and forefinger. The skin fold should be maintained throughout the injection. Do not rub the injection site after administration.

Children

The safety and efficacy of Enoxaparin Ledraxen in children and adolescents have not been established in large controlled clinical trials. However, enoxaparin is used off-label in paediatric patients in many centres worldwide. Paediatric dosing differs significantly from adult dosing because children, particularly infants, have higher volume of distribution and faster clearance of enoxaparin.

When used in paediatric populations, dosing is typically guided by anti-Factor Xa levels. General guidelines suggest treatment doses of 1.5 mg/kg twice daily for infants under 2 months and 1 mg/kg twice daily for older children. Prophylactic doses are approximately half the treatment dose. Paediatric prescribing should only be done by specialists experienced in paediatric anticoagulation, and anti-Factor Xa monitoring is essential.

Elderly

Elderly patients, particularly those over 75 years, are at increased risk of bleeding complications with enoxaparin. This is primarily due to age-related decline in renal function, even when serum creatinine levels appear normal. The ACCP and ESC guidelines recommend that renal function (estimated creatinine clearance) be assessed before starting enoxaparin in elderly patients, and dose adjustments should be made for those with impaired renal function.

For patients with severe renal impairment (creatinine clearance <30 mL/min), the dose should be reduced. For prophylaxis, a dose of 20 mg (2,000 IU) once daily is recommended regardless of the standard dose for the indication. For treatment, the dose should be reduced to 1 mg/kg once daily (rather than twice daily). Anti-Factor Xa monitoring may be considered to ensure appropriate anticoagulation without excessive drug accumulation.

Missed Dose

If you miss a dose of Enoxaparin Ledraxen, take it as soon as you remember, provided it is not too close to the time of your next scheduled dose. If it is nearly time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not inject a double dose to make up for a missed one. If you are unsure about what to do after missing a dose, contact your healthcare provider or pharmacist for advice.

Overdose

Accidental overdose of enoxaparin, whether by intravenous, extracorporeal, or subcutaneous administration, may lead to haemorrhagic complications. Symptoms of overdose include unexpected or excessive bleeding, bruising, blood in urine or stools, or signs of internal bleeding such as dizziness, weakness, or low blood pressure.

In the event of overdose, protamine sulfate is the specific antidote. One milligram of protamine sulfate neutralises approximately the anti-Factor IIa activity of 1 mg (100 IU) of enoxaparin. However, protamine only partially reverses the anti-Factor Xa activity of enoxaparin (approximately 60% neutralisation). Even with full doses of protamine, the anti-Factor Xa activity is never completely neutralised. If bleeding continues, additional protamine may be given, but clinical judgement is required as excess protamine can itself cause anticoagulation.

What Are the Side Effects of Enoxaparin Ledraxen?

Quick Answer: The most common side effects of Enoxaparin Ledraxen are bleeding (which can range from minor bruising to serious haemorrhage), injection site reactions (pain, bruising, haematoma), and elevated liver enzymes. Heparin-induced thrombocytopenia (HIT) is rare but potentially life-threatening and requires immediate medical attention.

Like all medicines, Enoxaparin Ledraxen can cause side effects, although not everybody gets them. The most important and frequently observed adverse effect is bleeding, which is inherent to the pharmacological action of the medicine. Bleeding can occur at any site and can range from minor (e.g., bruising at the injection site) to major, life-threatening haemorrhage. The risk of bleeding is influenced by the dose, the duration of treatment, the patient's age, renal function, body weight, and concomitant use of other medicines that affect haemostasis.

Clinical trials and post-marketing surveillance have provided comprehensive data on the frequency and types of adverse effects associated with enoxaparin. The following classification uses the standard frequency categories defined by the Council for International Organizations of Medical Sciences (CIOMS) and adopted by the EMA.

Long-term Side Effects

Prolonged use of enoxaparin (typically more than 3 months) has been associated with an increased risk of osteoporosis (thinning of the bones) due to effects on bone metabolism. This risk appears to be lower with LMWHs compared to unfractionated heparin, but it is still a consideration for patients requiring long-term anticoagulation, such as pregnant women or patients with cancer-associated thrombosis. Bone density monitoring may be considered in patients on prolonged therapy.

Alopecia (hair loss) has been reported rarely during treatment with heparin-class medicines including enoxaparin. This is typically diffuse and reversible upon discontinuation of therapy. If you notice significant hair thinning during treatment, discuss this with your healthcare provider.

How Should You Store Enoxaparin Ledraxen?

Quick Answer: Store Enoxaparin Ledraxen below 25°C (77°F). Do not freeze. Keep the pre-filled syringes in their original packaging to protect from light. Do not use after the expiry date printed on the carton and syringe label.

Proper storage of Enoxaparin Ledraxen is essential to ensure the medicine remains effective and safe to use. Incorrect storage can cause degradation of the active substance, potentially leading to reduced efficacy or unexpected adverse effects. The following storage guidelines should be followed carefully:

• Temperature: Store at or below 25°C (77°F). Do not expose to excessive heat. Room temperature storage is acceptable for the duration of the stated shelf life.
• Do not freeze: Freezing can damage the protein structure of enoxaparin and must be avoided. If a syringe has been frozen, it should be discarded and not used.
• Light protection: Keep the pre-filled syringes in the original outer carton to protect from light until ready for use.
• Expiry date: Do not use Enoxaparin Ledraxen after the expiry date shown on the carton and syringe label (EXP). The expiry date refers to the last day of that month.
• Keep out of reach of children: Store all medicines in a safe place where children cannot access them.
• Disposal: Do not dispose of used syringes in household waste. Used syringes and needles should be placed in a sharps disposal container. Ask your pharmacist how to dispose of medicines and sharps containers you no longer use.

Before each injection, visually inspect the solution. The solution should be clear and colourless to slightly yellowish. Do not use the syringe if the solution appears discoloured, cloudy, or contains visible particles. Do not use the syringe if it appears damaged or if the needle cap is missing or loose.

What Does Enoxaparin Ledraxen Contain?

Quick Answer: Each pre-filled syringe of Enoxaparin Ledraxen contains enoxaparin sodium as the active substance (2,000 IU / 20 mg per 0.2 mL) dissolved in water for injections. Enoxaparin sodium is derived from porcine intestinal mucosa heparin through a controlled depolymerisation process.

Understanding the composition of your medicine can be important, particularly if you have allergies or dietary restrictions. Enoxaparin Ledraxen is a relatively simple formulation with few excipients:

Active Substance

Enoxaparin sodium – Each 0.2 mL pre-filled syringe contains 2,000 IU (equivalent to 20 mg) of enoxaparin sodium. Enoxaparin sodium is the sodium salt of enoxaparin, a low molecular weight heparin obtained by alkaline depolymerisation of the benzyl ester of heparin derived from porcine intestinal mucosa. The average molecular weight is approximately 4,500 daltons, with approximately 68% of the chains having a molecular weight below 2,000 daltons.

Excipients

• Water for injections – the solvent used to dissolve the active substance, providing the appropriate volume and tonicity for subcutaneous injection.

The pre-filled syringe formulation of Enoxaparin Ledraxen does not contain benzyl alcohol, latex, or any other preservatives. This makes it suitable for use in patients with benzyl alcohol sensitivity and in neonates or premature infants. The syringe components (barrel, plunger, and needle) are made of medical-grade materials. Patients with known pork allergy should discuss the porcine origin of enoxaparin with their healthcare provider before use.